Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort
Table 4
Self-reported on-study fracture among pharmacologically treateda POSSIBLE US subjects stratified by the National Osteoporosis Foundation treatment thresholds.
Number of subjects with FRAX score
FRAX predicted 10-year risk of ≥3% for hip fracture
FRAX predicted 10-year risk of ≥20% for major osteoporotic fracture
FRAX score ≥ intervention threshold for either hip or major osteoporotic fractures
N = 2,996 n (%)
Yes (N = 1,039) n (%)
No (N = 1,957) n (%)
P-value
Yes (N = 610) n (%)
No (N = 2,386) n (%)
P-value
Yes (N = 1,062) n (%)
No (N = 1,934) n (%)
P-value
No on-study fracture
2,623 (87.6)
865 (83.3)
1,758 (89.8)
<0.0001
492 (80.7)
2,131 (89.3)
<0.0001
885 (83.3)
1,738 (89.9)
<0.0001
Any on-study fracture
373 (12.5)
174 (16.8)
199 (10.2)
118 (19.3)
255 (10.7)
177 (16.7)
196 (10.1)
Any osteoporosis- related fracture
240 (8.0)
126 (12.1)
114 (5.8)
<0.0001
93 (15.3)
147 (6.2)
<0.0001
127 (12.0)
113 (5.8)
<0.0001
Hip fracture
48 (1.6)
34 (3.3)
14 (0.7)
<0.0001
30 (4.9)
18 (0.8)
<0.0001
35 (3.3)
13 (0.7)
<0.0001
Spine fracture
54 (1.8)
32 (3.1)
22 (1.1)
0.0001
29 (4.8)
25 (1.1)
<0.0001
32 (3.0)
22 (1.1)
0.0002
Nonhip/non- spine fracture
169 (5.6)
79 (7.6)
90 (4.6)
0.0007
52 (8.5)
117 (4.9)
0.0005
80 (7.5)
89 (4.6)
0.0009
Multiple osteoporosis- related fractures
72 (2.4)
41 (4.0)
31 (1.6)
0.0001
34 (5.6)
38 (1.6)
<0.0001
42 (4.0)
30 (1.6)
<0.0001
Subjects who reported the use of pharmacological monotherapy or combination therapy at study entry or initiated pharmacological therapy within 2 months of entry. P value is for pairwise (yes/no) comparisons with percentage of specified fracture risk outcome for each risk category.
